|
Canada-0-MATTRESSES 公司名錄
|
公司新聞:
- Rechallenge therapy versus tyrosine kinase inhibitor (TKI . . .
Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for
- Lost in translation: Revisiting the use of tyrosine kinase . . .
Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment
- Zanzalintinib Atezolizumab Improves CRC Survival, Expands TKI . . .
New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options
- RETRACTED ARTICLE: Rechallenge therapy versus tyrosine kinase . . .
Colorectal cancer (CRC) is the third most common cause of cancer and the second most common cause of cancer-related death worldwide At least 50% of patients will experience metastasis, with the
- 96P Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI . . .
96P Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study J Zhang 1 ∙ Q Dong
- Treating Metastatic CRC With TKI I-O Combinations - OncLive
The rationale for continuing to study the combination of immunotherapies with novel tyrosine kinase inhibitors in metastatic colorectal cancer
- 5 FDA Developments From February: Kinase Inhibitors, GLP-1s . . .
The FDA approved kinase inhibitors, biologics, a pancreatic cancer device, GLP-1 updates, and a new ultrarare disease pathway in February 2026
- ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for . . .
The efficacy of combining TKI with PD-1 inhibitor in the treatment of advanced MSS pMMR colorectal cancer with low levels of maxVAF in peripheral blood ctDNA failed with standard treatment was assessed, compared to standard treatment as chosen by researchers
- Metastatic Cancer: When Cancer Spreads - NCI
Metastatic cancer is cancer that spreads from its site of origin to another part of the body Learn how cancer spreads, possible symptoms, common sites where cancer spreads, and how to find out about treatment options
- Rechallenge therapy versus tyrosine kinase inhibitor (TKI . . .
Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy This study aims to evaluate the efficacy and survival outcomes of tyrosine ki …
|
|